|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-2-8
|
|
pubmed:abstractText |
The predictor for the result of calcitriol therapy would be useful in the clinical practice of secondary hyperparathyroidism. Fibroblast growth factor-23 (FGF-23) is a newly found circulating phosphaturic factor. Its circulating level is elevated in uremia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0085-2538
|
|
pubmed:author |
pubmed-author:FukagawaMasafumiM,
pubmed-author:FukumotoSeijiS,
pubmed-author:GejyoFumitakeF,
pubmed-author:HamaHitomiH,
pubmed-author:KazamaJunichiro JJJ,
pubmed-author:MaruyamaHirokiH,
pubmed-author:NaritaIchieiI,
pubmed-author:OmoriKentaroK,
pubmed-author:SatoFuminoriF,
pubmed-author:YamamotoSuguruS,
pubmed-author:YamashitaTakeyoshiT
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1120-5
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.
|
|
pubmed:affiliation |
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. jjkaz@med.niigata-u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
